US4663285A
(en)
*
|
1981-01-06 |
1987-05-05 |
The Public Health Laboratory Service Board |
Chimeric plasmids
|
JPS58116498A
(ja)
*
|
1981-12-28 |
1983-07-11 |
Takeda Chem Ind Ltd |
Il‐2をコードする新規伝令rnaの製造法
|
EP0091539B2
(de)
*
|
1982-03-31 |
1996-11-27 |
Ajinomoto Co., Inc. |
Das Polypeptid Interleukin-2 kodierendes Gen, rekombinante, dieses Gen enthaltende DNA, diese rekombinante DNA aufweisende Zelllinien und Verfahren zur Herstellung von Interleukin-2 unter Verwendung der genannten Zellen
|
US4925919A
(en)
*
|
1984-04-25 |
1990-05-15 |
Roland Mertelsmann |
Purified interleukin 2
|
US4992271A
(en)
*
|
1982-09-23 |
1991-02-12 |
Cetus Corporation |
Formulation for lipophilic IL-2 proteins
|
AU575301B2
(en)
*
|
1982-10-08 |
1988-07-28 |
Juridical Foundation, Japanese Foundation For Cancer Research |
Novel vector
|
US4853332A
(en)
*
|
1982-10-19 |
1989-08-01 |
Cetus Corporation |
Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
|
US5700913A
(en)
*
|
1982-12-15 |
1997-12-23 |
Ajinomoto Co., Inc. |
Unglycosylated human interleukin-2 polypeptides
|
AU579089B2
(en)
*
|
1983-02-08 |
1988-11-17 |
Biogen, Inc. |
Human interleukin-2-like polypeptides
|
IL71275A0
(en)
*
|
1983-03-21 |
1984-06-29 |
Sparamedica Ag |
Human interleukin-2-and its preparation
|
US4518584A
(en)
*
|
1983-04-15 |
1985-05-21 |
Cetus Corporation |
Human recombinant interleukin-2 muteins
|
WO1985000817A1
(en)
*
|
1983-08-10 |
1985-02-28 |
Amgen |
Microbial expression of interleukin ii
|
US4695542A
(en)
*
|
1983-10-04 |
1987-09-22 |
Dnax Research Institute Of Molecular And Cellular Biology, Inc. |
cDNA clones coding for polypeptides exhibiting multi-lineage cellular growth factor activity
|
GB8327880D0
(en)
*
|
1983-10-18 |
1983-11-16 |
Ajinomoto Kk |
Saccharomyces cerevisiae
|
US5639639A
(en)
*
|
1983-11-02 |
1997-06-17 |
Genzyme Corporation |
Recombinant heterodimeric human fertility hormones, and methods, cells, vectors and DNA for the production thereof
|
JPS61500586A
(ja)
*
|
1983-11-14 |
1986-04-03 |
チロン コ−ポレイシヨン |
インタ−ロイキン−2産生のための方法及び組成物
|
JPS60115528A
(ja)
*
|
1983-11-28 |
1985-06-22 |
Takeda Chem Ind Ltd |
ヒトインタ―ロイキン―2蛋白質を含有する抗腫瘍用または免疫機能低下疾患治療用組成物
|
DK174501B1
(da)
*
|
1983-12-23 |
2003-04-28 |
Hoffmann La Roche |
Fremgangsmåde til fremstilling af interleukin-2
|
FR2559782B1
(fr)
*
|
1984-02-16 |
1986-07-18 |
Transgene Sa |
Vecteur d'expression dans les levures de l'interleukine-2, levures transformees et procede de preparation de l'interleukine-2
|
WO1985004328A1
(en)
|
1984-03-28 |
1985-10-10 |
Cetus Corporation |
Pharmaceutical compositions of microbially produced interleukin-2
|
US4569790A
(en)
*
|
1984-03-28 |
1986-02-11 |
Cetus Corporation |
Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
|
US4530787A
(en)
*
|
1984-03-28 |
1985-07-23 |
Cetus Corporation |
Controlled oxidation of microbially produced cysteine-containing proteins
|
EP0158198A1
(de)
*
|
1984-03-29 |
1985-10-16 |
Takeda Chemical Industries, Ltd. |
DNA und ihre Verwendung
|
US4908434A
(en)
*
|
1984-04-25 |
1990-03-13 |
Sloan-Kettering Institute For Cancer Research |
Process for preparing purified interleukin-2
|
US4908433A
(en)
*
|
1984-04-25 |
1990-03-13 |
Sloan-Kettering Institute For Cancer Research |
Uses of interleukin-2
|
ATE48641T1
(de)
*
|
1984-05-08 |
1989-12-15 |
Genetics Inst |
Ein menschlicher t-zellwachstumsfaktor.
|
DE3419995A1
(de)
*
|
1984-05-29 |
1985-12-05 |
Hoechst Ag, 6230 Frankfurt |
Gentechnologisches verfahren zur herstellung von human-interleukin-2 und mittel zur durchfuehrung dieses verfahrens
|
EP0172619A1
(de)
*
|
1984-06-20 |
1986-02-26 |
Takeda Chemical Industries, Ltd. |
Transformand und dessen Verwendung
|
JPS6156078A
(ja)
*
|
1984-07-27 |
1986-03-20 |
Suntory Ltd |
酵母を宿主とする分泌発現ベクタ−
|
PT79506B
(en)
*
|
1984-08-08 |
1986-09-08 |
Quidel |
T-cell growth factor
|
IL76360A0
(en)
|
1984-09-26 |
1986-01-31 |
Takeda Chemical Industries Ltd |
Mutual separation of proteins
|
WO1986002068A1
(en)
*
|
1984-09-26 |
1986-04-10 |
Takeda Chemical Industries, Ltd. |
Mutual separation of proteins
|
EP0177357A1
(de)
*
|
1984-10-05 |
1986-04-09 |
Schering Biotech Corporation |
cDNA-Klone, die für Polypeptide kodieren, die Murin-Interleukin-2-Aktivität zeigen
|
US4798789A
(en)
*
|
1984-10-05 |
1989-01-17 |
Dnax Research Institute Of Molecular And Cellular Biology, Inc. |
cDNA clones coding for polypeptides exhibiting murine interleukin-2 activity
|
US5317087A
(en)
*
|
1984-11-13 |
1994-05-31 |
Immunex Corporation |
Purification of the IL-2 receptor
|
US4752585A
(en)
*
|
1985-12-17 |
1988-06-21 |
Cetus Corporation |
Oxidation-resistant muteins
|
US5116943A
(en)
*
|
1985-01-18 |
1992-05-26 |
Cetus Corporation |
Oxidation-resistant muteins of Il-2 and other protein
|
JPH0646957B2
(ja)
*
|
1985-03-11 |
1994-06-22 |
武田薬品工業株式会社 |
インタ−ロイキン−2の製造方法
|
JPS61225199A
(ja)
*
|
1985-03-29 |
1986-10-06 |
Kyowa Hakko Kogyo Co Ltd |
新規ヒトインタ−ロイキン2ポリペチド誘導体
|
FR2583770B1
(fr)
*
|
1985-06-21 |
1988-08-19 |
Transgene Sa |
Expression de l'il-2 humaine dans les cellules de mammiferes par un poxvirus recombine
|
DK402785D0
(da)
*
|
1985-09-03 |
1985-09-03 |
Syn Tek Ab |
Fremgangsmaade til fremstilling af et enzym
|
US5248603A
(en)
*
|
1985-09-03 |
1993-09-28 |
Symbicom Aktiebolag |
Superoxide dismutase
|
US5011684A
(en)
*
|
1985-09-05 |
1991-04-30 |
Beth Israel Hospital Association |
Lysing or blocking unwanted cells with IL-2 receptor-specific binding substance
|
US5336489A
(en)
*
|
1985-09-05 |
1994-08-09 |
The Beth Israel Hospital Association |
Treatment of allograft rejection with IL-2 receptor-specific cytotoxins
|
US4816440A
(en)
*
|
1985-09-26 |
1989-03-28 |
Cetus Corporation |
Stable formulation of biologically active proteins for parenteral injection
|
US5496924A
(en)
*
|
1985-11-27 |
1996-03-05 |
Hoechst Aktiengesellschaft |
Fusion protein comprising an interleukin-2 fragment ballast portion
|
US5359035A
(en)
*
|
1985-12-21 |
1994-10-25 |
Hoechst Aktiengesellschaft |
Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
|
US4933433A
(en)
*
|
1986-01-31 |
1990-06-12 |
E. I. Du Pont De Nemours And Company |
Recombinant interleukin-2 composition and process for making it
|
US5425940A
(en)
*
|
1986-04-09 |
1995-06-20 |
Cetus Oncology Corporation |
Combination therapy using interleukin-2 and tumor necrosis factor
|
US4992367A
(en)
*
|
1986-05-12 |
1991-02-12 |
Hoffmann-La Roche Inc. |
Enhanced expression of human interleukin-2 in mammalian cells
|
US4939093A
(en)
*
|
1987-02-02 |
1990-07-03 |
Cetus Corporation |
Human IL-2 like polypeptides, DNA sequences and recombinant DNA molecules therefore and methods for the production and use thereof
|
US5149788A
(en)
*
|
1987-05-19 |
1992-09-22 |
Hoffmann-La Roche, Inc. |
Purification of chimeric proteins containing an IL-2 moiety by receptor-affinity chromatography
|
US5162503A
(en)
*
|
1987-05-19 |
1992-11-10 |
Hoffmann-La Roche, Inc. |
Purification of interleukin-2 by receptor-affinity chromatography
|
US4956281A
(en)
*
|
1987-06-03 |
1990-09-11 |
Biogen, Inc. |
DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
|
US5152980A
(en)
*
|
1988-05-19 |
1992-10-06 |
The Beth Israel Hospital Association |
Induction of tolerance to a foreign antigen IL-2 receptor-binding substances
|
US5185441A
(en)
*
|
1988-08-26 |
1993-02-09 |
Biogen, Inc. |
Dna sequences, recombinant dna molecules and processes for producing pi-linked lymphocyte function associated antigen-3
|
US6867195B1
(en)
|
1989-03-21 |
2005-03-15 |
Vical Incorporated |
Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
|
US6214804B1
(en)
|
1989-03-21 |
2001-04-10 |
Vical Incorporated |
Induction of a protective immune response in a mammal by injecting a DNA sequence
|
US5703055A
(en)
*
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
US6673776B1
(en)
|
1989-03-21 |
2004-01-06 |
Vical Incorporated |
Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
|
US6899882B1
(en)
*
|
1989-03-24 |
2005-05-31 |
The Regents Of The University Of California |
Endothelial cell growth factor methods of isolation and expression
|
WO1990012877A1
(en)
*
|
1989-04-19 |
1990-11-01 |
Cetus Corporation |
Multifunctional m-csf proteins and genes encoding therefor
|
DK455789D0
(da)
*
|
1989-09-15 |
1989-09-15 |
Symbicom Ab |
Polypeptid
|
WO1991005052A1
(en)
*
|
1989-09-28 |
1991-04-18 |
Leningradsky Gosudarstvenny Universitet |
Method for obtaining a polypeptide with human-interleukin-2 activity, secreted by yeast cells, saccharomyces cerevisiae
|
EP0500799B1
(de)
*
|
1989-11-16 |
1998-01-14 |
Duke University |
Transformation von tierischen Hautzellen mit hilfe von Partikeln
|
US6228844B1
(en)
|
1991-11-12 |
2001-05-08 |
Vical Incorporated |
Stimulating vascular growth by administration of DNA sequences encoding VEGF
|
US6706694B1
(en)
|
1990-03-21 |
2004-03-16 |
Vical Incorporated |
Expression of exogenous polynucleotide sequences in a vertebrate
|
US20030186913A1
(en)
*
|
1990-03-21 |
2003-10-02 |
Vical Incorporated |
Expression of exogenous polynucleotide sequences in a vertebrate
|
US5830452A
(en)
*
|
1990-11-20 |
1998-11-03 |
Chiron Corporation |
Method for enhancing the anti-tumor therapeutic index of interleukin-2
|
US5250296A
(en)
*
|
1990-11-29 |
1993-10-05 |
Takeda Chemical Industries, Ltd. |
Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine
|
US6764681B2
(en)
*
|
1991-10-07 |
2004-07-20 |
Biogen, Inc. |
Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
|
US5449691A
(en)
*
|
1991-12-31 |
1995-09-12 |
Sterling Winthrop Inc. |
3,4-disubstituted anilines-immunomodulating agents
|
US5258407A
(en)
*
|
1991-12-31 |
1993-11-02 |
Sterling Winthrop Inc. |
3,4-disubstituted phenols-immunomodulating agents
|
FR2686899B1
(fr)
*
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
US6806084B1
(en)
|
1992-06-04 |
2004-10-19 |
The Regents Of The University Of California |
Methods for compositions for in vivo gene delivery
|
WO1994018995A1
(en)
*
|
1993-02-17 |
1994-09-01 |
Sloan-Kettering Institute For Cancer Research |
Allogeneic vaccine and method to synthesize same
|
CA2158937C
(en)
|
1993-09-15 |
2006-01-03 |
Thomas W. Dubensky, Jr. |
Recombinant alphavirus vectors
|
US5641665A
(en)
*
|
1994-11-28 |
1997-06-24 |
Vical Incorporated |
Plasmids suitable for IL-2 expression
|
US5686246A
(en)
*
|
1995-08-03 |
1997-11-11 |
Kornman; Kenneth S. |
Detecting genetic predisposition to periodontal disease
|
JPH09151200A
(ja)
*
|
1995-09-29 |
1997-06-10 |
Ajinomoto Co Inc |
ヒト胃癌に対する免疫応答を誘導できるペプチド及び該ペプチドを含むヒト胃癌治療、予防剤
|
DK0938320T3
(da)
*
|
1996-03-26 |
2010-10-18 |
Michael S Kopreski |
Metode til at ud af plasma eller serum tilvejebringe ekstraheret ekstracellulært RNA for at detektere, overvåge eller vurdere cancer
|
US8043835B1
(en)
|
1996-03-26 |
2011-10-25 |
Oncomedx, Inc. |
Methods for detecting and monitoring cancer using extracellular RNA
|
US6759217B2
(en)
*
|
1996-03-26 |
2004-07-06 |
Oncomedx, Inc. |
Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
|
US7785842B2
(en)
*
|
1996-03-26 |
2010-08-31 |
Oncomedx, Inc. |
Comparative analysis of extracellular RNA species
|
ES2301178T3
(es)
|
1996-04-05 |
2008-06-16 |
Novartis Vaccines & Diagnostic |
Vectores basados en alfavirus recombinantes con inhibicion reducida de la sintesis macromolecular celular.
|
CA2266656A1
(en)
|
1996-09-17 |
1998-03-26 |
Chiron Corporation |
Compositions and methods for treating intracellular diseases
|
US6008319A
(en)
*
|
1996-12-23 |
1999-12-28 |
University Of Southern California |
Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
|
US6034072A
(en)
*
|
1997-02-10 |
2000-03-07 |
Genemedicine, Inc. |
IL-2 gene expression and delivery systems and uses
|
US20070009934A1
(en)
*
|
1997-03-14 |
2007-01-11 |
Kopreski Michael S |
Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
|
US8440396B2
(en)
*
|
1997-03-14 |
2013-05-14 |
Oncomedx, Inc. |
Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
|
US6251866B1
(en)
|
1997-08-05 |
2001-06-26 |
Watson Laboratories, Inc. |
Conjugates targeted to the interleukin-2 receptor
|
US6306589B1
(en)
*
|
1998-05-27 |
2001-10-23 |
Vysis, Inc. |
Biological assays for analyte detection
|
US6168785B1
(en)
*
|
1998-07-16 |
2001-01-02 |
Institut Pasteur |
Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
|
WO2000012113A2
(en)
*
|
1998-08-31 |
2000-03-09 |
Biogen, Inc. |
Method of modulating memory effector t-cells using a cd2-binding agent, and compositions
|
US8163524B2
(en)
*
|
1998-09-22 |
2012-04-24 |
Oncomedx, Inc. |
Comparative analysis of extracellular RNA species
|
US20080261292A1
(en)
*
|
1998-09-22 |
2008-10-23 |
Oncomedx, Inc. |
Method Enabling the Use of Extracellular Ribonucleic Acid (RNA) Extracted from Plasma or Serum to Detect, Monitor or Evaluate Cancer or Premalignant Conditions
|
US20060204989A1
(en)
*
|
1998-09-22 |
2006-09-14 |
Kopreski Michael S |
Comparative analysis of extracellular RNA species
|
WO2000039302A2
(en)
|
1998-12-31 |
2000-07-06 |
Chiron Corporation |
Improved expression of hiv polypeptides and production of virus-like particles
|
US7935805B1
(en)
|
1998-12-31 |
2011-05-03 |
Novartis Vaccines & Diagnostics, Inc |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
US7662368B2
(en)
*
|
1999-07-16 |
2010-02-16 |
Institut Pasteur |
Method of inducing SHC phosphorylation of inducing the SHC/MAPK pathway by administering a peptide of IL-2
|
EP1935431A3
(de)
|
2000-05-15 |
2008-08-13 |
Health Research, Inc. |
Krebsbehandlungen unter Verwendung einer Kombination aus einem HER2-Antikörper und Interleukin-2
|
US20070025958A1
(en)
|
2000-10-27 |
2007-02-01 |
Hadden John W |
Vaccine immunotherapy
|
WO2002088370A2
(en)
*
|
2001-04-30 |
2002-11-07 |
Protiva Biotherapeutics Inc. |
Autogene nucleic acids encoding a secretable rna polymerase
|
US20030003074A1
(en)
*
|
2001-06-14 |
2003-01-02 |
Macromed, Inc. |
Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
|
US20060159657A1
(en)
*
|
2001-06-14 |
2006-07-20 |
Macromed, Incorporated |
Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
|
EP1409694A4
(de)
|
2001-07-05 |
2006-02-08 |
Chiron Corp |
Antigene typ-b- und/oder typ-c-hiv-polypeptide codierende polynukleotide, polypeptide und deren verwendungen
|
CA2452015C
(en)
|
2001-07-05 |
2012-07-03 |
Chiron Corporation |
Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
|
AU2002320352A1
(en)
*
|
2001-07-24 |
2003-02-17 |
Biogen Idec Ma Inc. |
Methods for treating or preventing sclerotic disorders using cd2-binding agents
|
AU2002327308A1
(en)
*
|
2001-07-25 |
2003-02-17 |
Oncomedx Inc. |
Methods for evaluating pathologic conditions using extracellular rna
|
US20030104454A1
(en)
*
|
2001-11-05 |
2003-06-05 |
Kopreski Michael S. |
Method for detection of DNA methyltransferase RNA in plasma and serum
|
US20100159464A1
(en)
*
|
2001-11-05 |
2010-06-24 |
Oncomedx, Inc. |
Method for Detection of DNA Methyltransferase RNA in Plasma and Serum
|
EP2261250B1
(de)
|
2001-12-21 |
2015-07-01 |
Human Genome Sciences, Inc. |
GCSF-Albumin Fusionsproteine
|
EP1497437A4
(de)
|
2002-05-01 |
2005-11-16 |
Cell Genesys Inc |
Gegenüber komplement-inaktivierung resistente lentivirus-vektorpartikel
|
AU2002304965A1
(en)
|
2002-05-24 |
2003-12-12 |
Zensun (Shanghai) Sci-Tech.Ltd |
Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
|
CA2544853C
(en)
|
2003-11-04 |
2014-05-20 |
Chiron Corporation |
Use of antagonist anti-cd40 antibodies for treatment of autoimmune and inflammatory diseases, and organ transplant rejection
|
US20070172478A1
(en)
*
|
2004-02-06 |
2007-07-26 |
Astellas Us Llc |
Methods of treating skin disorders
|
WO2005115436A1
(en)
*
|
2004-05-07 |
2005-12-08 |
Astellas Us Llc |
Soluble lfa-3 polypeptide for treating viral disorders
|
EP2266602A3
(de)
|
2004-11-01 |
2011-08-10 |
Novartis Vaccines and Diagnostics, Inc. |
Kombinationswege zur Erzeugung von Immunantworten
|
BRPI0608186A2
(pt)
*
|
2005-02-18 |
2011-01-04 |
Synthasome Inc |
estrutura sintética para reparo de tecidos moles
|
US20100010068A1
(en)
*
|
2005-08-19 |
2010-01-14 |
Binhai Ren |
Liver-directed gene therapy
|
US20100196336A1
(en)
|
2006-05-23 |
2010-08-05 |
Dongsu Park |
Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
|
US20090136942A1
(en)
*
|
2007-09-18 |
2009-05-28 |
Oncomedx, Inc. |
Analysis of Extracellular RNA
|
JP2011505011A
(ja)
*
|
2007-11-28 |
2011-02-17 |
スマート チューブ,インコーポレイテッド |
生体試料の採取、刺激、安定化及び分析のためのデバイス、システム及び方法
|
EP2248903A1
(de)
|
2009-04-29 |
2010-11-10 |
Universitat Autònoma De Barcelona |
Verfahren und Reagenzien zum effizienten und gezielten Gentransfer in Monozyten und Makrophagen
|
US10119959B2
(en)
*
|
2010-06-25 |
2018-11-06 |
The Board Of Trustees Of The Leland Stanford Junior University |
Method of assaying an individual for immune impairment
|
SG10201509790YA
(en)
|
2010-11-30 |
2015-12-30 |
Chugai Pharmaceutical Co Ltd |
Antigen-Binding Molecule Capable Of Binding To Plurality Of Antigen Molecules Repeatedly
|
US9428567B2
(en)
|
2010-12-22 |
2016-08-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Antagonists of interleukin-2 receptor
|
CN103492565B
(zh)
|
2011-02-25 |
2021-01-29 |
中外制药株式会社 |
FcγRIIb特异性Fc抗体
|
EP2714912B1
(de)
|
2011-06-01 |
2018-05-02 |
Intrexon Actobiotics NV |
Polycistronisches expressionssystem für bakterien
|
EP2762493B1
(de)
|
2011-09-30 |
2021-06-09 |
Chugai Seiyaku Kabushiki Kaisha |
Antigenbindende moleküle zur förderung der zersetzung von antigenen mit mehreren biologischen aktivitäten
|
KR20210074395A
(ko)
|
2011-11-30 |
2021-06-21 |
추가이 세이야쿠 가부시키가이샤 |
면역 복합체를 형성하는 세포내로의 운반체(캐리어)를 포함하는 의약
|
NZ627992A
(en)
|
2012-02-07 |
2017-02-24 |
Global Bio Therapeutics Inc |
Compartmentalized method of nucleic acid delivery and compositions and uses thereof
|
US20140350087A9
(en)
|
2012-03-22 |
2014-11-27 |
Halozyme, Inc. |
Oncovector Nucleic Acid Molecules and Methods of Use
|
US9732144B2
(en)
|
2012-07-05 |
2017-08-15 |
Ohio State Innovation Foundation |
Infectious bursal disease (IBDV) vaccine compositions
|
JP6297692B2
(ja)
|
2013-08-08 |
2018-03-20 |
グローバル・バイオ・セラピューティクス・インコーポレイテッドGlobal Bio Therapeutics,Inc. |
低侵襲処置用クランプデバイスおよびその使用
|
US10781242B2
(en)
|
2013-09-24 |
2020-09-22 |
Medicenna Therapeutics Inc. |
Interleukin-2 fusion proteins and uses thereof
|
CA2946398A1
(en)
|
2014-04-24 |
2015-10-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superagonists, partial agonists and antagonists of interleukin-2
|
EP2940128A1
(de)
|
2014-04-30 |
2015-11-04 |
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) |
Adenovirus mit einem albuminbindenden Teil
|
CA2996762A1
(en)
|
2015-08-31 |
2017-03-09 |
Technovax, Inc. |
Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine
|
CN108883140A
(zh)
|
2016-01-14 |
2018-11-23 |
英特瑞克斯顿阿克图比奥帝克斯有限公司 |
治疗1型糖尿病的组合物和方法
|
WO2017180770A1
(en)
|
2016-04-13 |
2017-10-19 |
Synthetic Genomics, Inc. |
Recombinant arterivirus replicon systems and uses thereof
|
CA3040264A1
(en)
|
2016-10-17 |
2018-04-26 |
Synthetic Genomics, Inc. |
Recombinant virus replicon systems and uses thereof
|
CN110352247A
(zh)
|
2016-12-05 |
2019-10-18 |
杨森制药公司 |
用于增强基因表达的组合物和方法
|
US11542312B2
(en)
|
2017-06-19 |
2023-01-03 |
Medicenna Therapeutics, Inc. |
IL-2 superagonists in combination with anti-PD-1 antibodies
|
EA202091516A1
(ru)
|
2017-12-19 |
2020-11-03 |
Янссен Сайенсиз Айрлэнд Анлимитед Компани |
Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
|
US11021692B2
(en)
|
2017-12-19 |
2021-06-01 |
Janssen Sciences Ireland Unlimited Company |
Hepatitis B virus (HBV) vaccines and uses thereof
|
US11389531B2
(en)
|
2017-12-19 |
2022-07-19 |
Janssen Sciences Ireland Unlimited Company |
Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
|
CN111902163B
(zh)
|
2018-01-19 |
2024-02-13 |
杨森制药公司 |
使用重组复制子系统诱导和增强免疫应答
|
EP4034144A1
(de)
|
2019-09-27 |
2022-08-03 |
Intrexon Actobiotics NV d/b/a Precigen Actobio |
Behandlung von zöliakie
|
CN115362168A
(zh)
|
2020-01-14 |
2022-11-18 |
辛德凯因股份有限公司 |
偏向化il2突变蛋白方法和组合物
|